本文已被:浏览 362次 下载 307次
Received:April 24, 2023 Published Online:September 19, 2023
Received:April 24, 2023 Published Online:September 19, 2023
中文摘要: 晚期胃癌患者的生存率低,生活质量差。尽管晚期胃癌的化疗方案在不断发展与改善,晚期胃癌患者的生存率仍然较低。目前,晚期胃癌不仅综合治疗手段十分有限,后线治疗手段也十分缺乏,因而亟需针对晚期胃癌的有效治疗方案。近年来,随着对肿瘤免疫学的深入研究,免疫治疗成为人们关注的焦点。程序性死亡受体-1(PD-1)抑制剂作为一种免疫抑制剂,将其与化疗结合起来,不仅能最大限度地发挥免疫抑制剂的临床活性,还可以建立持久的免疫反应。目前,PD-1抑制剂联合铂类化疗已在晚期胃癌的临床研究中显示出较高的临床应用价值。本文对晚期胃癌的PD-1抑制剂联合化疗方案的研究进展进行综述,旨在为其临床应用提供依据。
Abstract:The survival rate and quality of life of patients with advanced gastric cancer are low. Despite the continuous development and improvement of chemotherapy regimens for advanced gastric cancer, the survival rate of patients with advanced gastric cancer is still low. At present, not only are comprehensive treatment methods very limited for advanced gastric cancer, but there is also a lack of posterior treatment methods. Therefore, there is an urgent need for effective treatment plans for advanced gastric cancer. In recent years, with the in-depth research on tumor immunology, immunotherapy has become a focus of attention. Programmed cell death protein-1 (PD-1) inhibitor, as an immunosuppressive drug, combined with chemotherapy, can not only maximize the clinical activity of immunosuppressive drug, but also establish a lasting immune response. At present, the combination of PD-1 inhibitors and platinum chemotherapy has shown high clinical application value in clinical research of advanced gastric cancer. This article reviews the research progress of PD-1 inhibitors combined with chemotherapy for advanced gastric cancer, aiming to provide a basis for clinical application.
keywords: Advanced gastric cancer Programmed cell death protein-1 inhibitor Immunotherapy Chemotherapy Sintilimab Pembrolizumab Nivolumab Camrelizumab Tislelizumab
文章编号: 中图分类号:R735.2 文献标志码:A
基金项目:甘肃省自然科学基金(21JRIRA126);希思科—恒瑞肿瘤研究基金项目(Y-HR2018-147)
引用文本: